BR112022022899A2 - Agonistas de il10 e métodos de uso dos mesmos - Google Patents
Agonistas de il10 e métodos de uso dos mesmosInfo
- Publication number
- BR112022022899A2 BR112022022899A2 BR112022022899A BR112022022899A BR112022022899A2 BR 112022022899 A2 BR112022022899 A2 BR 112022022899A2 BR 112022022899 A BR112022022899 A BR 112022022899A BR 112022022899 A BR112022022899 A BR 112022022899A BR 112022022899 A2 BR112022022899 A2 BR 112022022899A2
- Authority
- BR
- Brazil
- Prior art keywords
- agonists
- methods
- relates
- present
- therapeutic efficacy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5428—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2066—IL-10
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063023703P | 2020-05-12 | 2020-05-12 | |
| PCT/US2021/031806 WO2021231447A1 (en) | 2020-05-12 | 2021-05-11 | Novel il10 agonists and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022022899A2 true BR112022022899A2 (pt) | 2022-12-20 |
Family
ID=76181307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022022899A BR112022022899A2 (pt) | 2020-05-12 | 2021-05-11 | Agonistas de il10 e métodos de uso dos mesmos |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11673930B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4149963A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7827640B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230009430A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115667290A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021270563A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022022899A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3183151A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL298007A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022014239A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021231447A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202210918B (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024249957A2 (en) * | 2023-06-01 | 2024-12-05 | Synthekine, Inc. | Il10 inverted monomers |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| JP3051145B2 (ja) | 1990-08-28 | 2000-06-12 | 住友製薬株式会社 | 新規なポリエチレングリコール誘導体修飾ペプチド |
| US5582996A (en) | 1990-12-04 | 1996-12-10 | The Wistar Institute Of Anatomy & Biology | Bifunctional antibodies and method of preparing same |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| CA2128511C (en) | 1992-01-23 | 2006-11-07 | Andreas Pluckthun | Monomeric and dimeric antibody-fragment fusion proteins |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6410008B1 (en) | 1994-12-12 | 2002-06-25 | Beth Israel Hospital Association | Chimeric IL-10 proteins and uses thereof |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| GB9720054D0 (en) | 1997-09-19 | 1997-11-19 | Celltech Therapeutics Ltd | Biological products |
| GB9824437D0 (en) | 1998-11-06 | 1999-01-06 | Ylo Herttuala Seppo | Gene therapy |
| US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| US7261882B2 (en) | 2003-06-23 | 2007-08-28 | Reagents Of The University Of Colorado | Methods for treating neuropathic pain by administering IL-10 polypeptides |
| PT1644412E (pt) | 2003-07-01 | 2015-12-23 | Ucb Biopharma Sprl | Fragmentos de anticorpos fab modificados |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| WO2005049094A1 (en) | 2003-11-13 | 2005-06-02 | Advantagene, Inc. | A mixed complementary viral vector for gene therapy |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| WO2007061657A2 (en) | 2005-11-14 | 2007-05-31 | The Brigham & Women's Hospital, Inc. | Interleukin-10 compositions for the treatment of adenocarcinomas |
| US20070179094A1 (en) * | 2006-01-31 | 2007-08-02 | Bayer Schering Pharma Ag | Modulation of MDL-1 activity for treatment of inflammatory disease |
| US20070269422A1 (en) | 2006-05-17 | 2007-11-22 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| US20100093076A1 (en) * | 2006-08-25 | 2010-04-15 | Moore Margaret D | Soluble il-27 receptor |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| WO2012045334A1 (en) * | 2010-10-05 | 2012-04-12 | Synthon Bv | Biologically active il-10 fusion proteins |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| US9346872B2 (en) | 2012-08-08 | 2016-05-24 | Roche Glycart Ag | Interleukin-10 fusion proteins |
| MX385344B (es) | 2012-11-28 | 2025-03-18 | Zymeworks Bc Inc | Pares de cadena pesada-cadena ligera de inmunoglobulina modificados genéticamente y usos de estos. |
| TWI682941B (zh) * | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
| US10047167B2 (en) | 2013-03-15 | 2018-08-14 | Eli Lilly And Company | Methods for producing fabs and bi-specific antibodies |
| EP2986306A4 (en) | 2013-04-18 | 2016-12-07 | Armo Biosciences Inc | METHOD FOR USE OF INTERLEUKIN-10 FOR THE TREATMENT OF ILLNESSES AND SUFFERING |
| KR20160079114A (ko) | 2013-11-11 | 2016-07-05 | 아르모 바이오사이언시스 인코포레이티드 | 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법 |
| BR112016016658A2 (pt) | 2014-02-06 | 2018-01-23 | F. Hoffmann-La Roche Ag | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão |
| AU2015336101A1 (en) | 2014-10-22 | 2017-04-20 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
| CN104403004B (zh) | 2014-11-24 | 2017-10-13 | 苏州丁孚靶点生物技术有限公司 | 抗体‑干扰素异二聚体的制备和用途 |
| EP3233920B1 (en) | 2014-12-19 | 2020-08-26 | Alkermes, Inc. | Single chain fc fusion proteins |
| DK3277725T3 (da) | 2015-03-30 | 2021-01-11 | Regeneron Pharma | Konstante tungkædeområder med reduceret binding til FC-gammareceptorer |
| WO2016191587A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
| WO2017087784A1 (en) | 2015-11-18 | 2017-05-26 | Duke University | Tumor infiltrating lymphocytes for treatment of cancer |
| RU2725292C2 (ru) * | 2016-04-27 | 2020-06-30 | Иммьюномедикс, Инк. | Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей |
| WO2017210684A1 (en) | 2016-06-03 | 2017-12-07 | New York University | Methods and reagents for modulating macrophage phenotype |
| WO2018005226A2 (en) | 2016-06-22 | 2018-01-04 | Alkermes, Inc. | Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties |
| CN110234355B (zh) | 2017-02-01 | 2021-11-09 | 浙江时迈药业有限公司 | 单体人IgG1 Fc和双特异性抗体 |
| JP7795181B2 (ja) * | 2017-09-06 | 2026-01-07 | イェール ユニバーシティー | インターロイキン－１８バリアントとその利用法 |
| CN111315398A (zh) * | 2017-11-10 | 2020-06-19 | 阿尔莫生物科技股份有限公司 | 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法 |
| WO2019152344A1 (en) * | 2018-01-30 | 2019-08-08 | University Of Louisville Research Foundation, Inc. | Compositions and methods for treating inflammation and cancer |
| EP3808376A4 (en) * | 2018-06-17 | 2021-09-01 | L&L Biopharma Co., Ltd. | CLDN18.2 ANTIBODY, BISPECIFIC ANTIBODY, ADC AND CAR, AND APPLICATIONS THEREOF |
| WO2020097946A1 (zh) | 2018-11-18 | 2020-05-22 | 杭州博虎生物科技有限公司 | 一种重组人白细胞介素10融合蛋白及其应用 |
| CN113811549A (zh) * | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
| US20220227827A1 (en) * | 2019-03-25 | 2022-07-21 | Dingfu Biotarget Co., Ltd. | Proteinaceous heterodimer and use thereof |
| JP7641912B2 (ja) * | 2019-04-19 | 2025-03-07 | シナーキン・ファーマ・ベスローテン・フエンノートシャップ | Ｉｌ１３を含む融合タンパク質 |
| EP3795583A1 (en) * | 2019-09-19 | 2021-03-24 | Ecole Polytechnique Federale de Lausanne (EPFL) | Il10/fc fusion proteins useful as enhancers of immunotherapies |
| WO2021158938A1 (en) * | 2020-02-06 | 2021-08-12 | Bristol-Myers Squibb Company | Il-10 and uses thereof |
-
2021
- 2021-05-11 KR KR1020227042884A patent/KR20230009430A/ko active Pending
- 2021-05-11 CN CN202180034885.5A patent/CN115667290A/zh active Pending
- 2021-05-11 CA CA3183151A patent/CA3183151A1/en active Pending
- 2021-05-11 BR BR112022022899A patent/BR112022022899A2/pt unknown
- 2021-05-11 WO PCT/US2021/031806 patent/WO2021231447A1/en not_active Ceased
- 2021-05-11 AU AU2021270563A patent/AU2021270563A1/en active Pending
- 2021-05-11 MX MX2022014239A patent/MX2022014239A/es unknown
- 2021-05-11 US US17/317,475 patent/US11673930B2/en active Active
- 2021-05-11 JP JP2022568853A patent/JP7827640B2/ja active Active
- 2021-05-11 IL IL298007A patent/IL298007A/en unknown
- 2021-05-11 EP EP21728784.6A patent/EP4149963A1/en active Pending
-
2022
- 2022-10-04 ZA ZA2022/10918A patent/ZA202210918B/en unknown
-
2023
- 2023-04-28 US US18/308,892 patent/US12187772B2/en active Active
-
2024
- 2024-11-22 US US18/956,670 patent/US20250333464A1/en active Pending
-
2025
- 2025-11-27 JP JP2025206113A patent/JP2026048706A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115667290A (zh) | 2023-01-31 |
| ZA202210918B (en) | 2025-12-17 |
| IL298007A (en) | 2023-01-01 |
| US20230279070A1 (en) | 2023-09-07 |
| WO2021231447A1 (en) | 2021-11-18 |
| MX2022014239A (es) | 2023-02-09 |
| CA3183151A1 (en) | 2021-11-18 |
| US20210355184A1 (en) | 2021-11-18 |
| JP7827640B2 (ja) | 2026-03-10 |
| KR20230009430A (ko) | 2023-01-17 |
| US12187772B2 (en) | 2025-01-07 |
| AU2021270563A1 (en) | 2022-12-15 |
| US20250333464A1 (en) | 2025-10-30 |
| EP4149963A1 (en) | 2023-03-22 |
| JP2023525555A (ja) | 2023-06-16 |
| JP2026048706A (ja) | 2026-03-17 |
| US11673930B2 (en) | 2023-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125358T1 (el) | Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων | |
| CO2019007298A2 (es) | Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos | |
| PH12021500001A1 (en) | Antibodies that target hiv gp120 and methods of use | |
| JOP20220008A1 (ar) | مثبطات parp1 | |
| BR112023006364A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e pembrolizumabe | |
| CL2019002850A1 (es) | Terapias combinadas dirigidas a pd-1, tim-3, y lag-3. | |
| MX2022002633A (es) | Mimeticos de hepcidina conjugada. | |
| BR112022002442A2 (pt) | Terapias de imuno-oncologia com conjugados de il-2 | |
| BR112022026236A2 (pt) | Terapia de combinação de imuno-oncologia com conjugados de il-2 e anticorpos anti-egfr | |
| BR112021008012A2 (pt) | Conjugados de anticorpo de cisteína engenheirada-fármaco com ligantes contendo peptídeo | |
| MX2021016050A (es) | Formulaciones transdermicas. | |
| BR112018000254A2 (pt) | inibidores de pde9 com cadeia principal de imidazotriazinona e cadeia principal de imidazopirazinona para o tratamento de doenças periféricas | |
| MX2021012359A (es) | Inhibidores de la vía de señalización de notch y su uso en el tratamiento de cánceres. | |
| TWD199277S (zh) | 電連接器 | |
| MX393900B (es) | Uso de gaboxadol en el tratamiento de tinnitus. | |
| MX2024006769A (es) | Compuestos y usos de los mismos. | |
| CY1120906T1 (el) | Συνθεσεις οξπρενολολης για τη θεραπεια του καρκινου | |
| CY1125014T1 (el) | Υποκατεστημενα παραγωγα ξανθινης | |
| MX384262B (es) | Gel intestinal de levodopa y carbidopa y metodos de uso. | |
| ZA202209674B (en) | Molecules targeting ras protein | |
| EP4512816A3 (en) | Tlr7 agonists | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| ZA202210918B (en) | Novel il10 agonists and methods of use thereof | |
| WO2020032902A3 (en) | Aksolotl blastema for use in the treatment of wounds and burns | |
| BR112022010165A2 (pt) | Agonistas de tlr7 |